Results 181 to 190 of about 32,646 (215)
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs [PDF]
International Journal of Molecular Sciences, 2017 Poly (ADP-ribose) polymerase 1 (PARP1), the best-studied isoform of the nuclear enzyme PARP family, plays a pivotal role in cellular biological processes, such as DNA repair, gene transcription, and so on. PARP1 has been found to be overexpressed in various carcinomas.
Fangfei Li, Aiping Lu, Daogang Guan
exaly +3 more sources
Increased PARP1‐DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1‐DNA trapping is correlated with PARP1 inhibitor's cytotoxicity [PDF]
International Journal of Cancer, 2019 PARP1 inhibitors (PARPis) are used clinically during cancer therapy and are thought to exert their cytotoxicity through PARP1 polymerase inhibition and PARP1‐DNA trapping. Here, we showed no significant correlation between PARP1‐DNA trapping and cytotoxicity induced by PARPis.
Ze-Hong Miao, Ne Guo, Yuting Wang
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Captured snapshots of PARP1 in the active state reveal the mechanics of PARP1 allostery
Molecular Cell, 2022PARP1 rapidly detects DNA strand break damage and allosterically signals break detection to the PARP1 catalytic domain to activate poly(ADP-ribose) production from NAD+. PARP1 activation is characterized by dynamic changes in the structure of a regulatory helical domain (HD); yet, there are limited insights into the specific contributions that the HD ...
John Pascal +2 more
exaly +3 more sources
Pleiotropic role of PARP1: an overview
3 Biotech, 2021Poly (ADP-ribose) polymerase 1 (PARP1) protein is encoded by the PARP1 gene located on chromosome 1 (1q42.12) in human cells. It plays a crucial role in post-translational modification by adding poly (ADP-ribose) (PAR) groups to various proteins and PARP1 itself by utilizing nicotinamide adenine dinucleotide (NAD +) as a substrate.
Vikas Kumar +4 more
openaire +2 more sources
PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention
Current Medicinal Chemistry, 2016Poly(ADP-ribose) polymerase 1 (PARP1) inhibition, increasing chemosensitization and conferring independent antiproliferation against defective homologous recombination cells, has provided a unique opportunity for anticancer therapeutic intervention.
Xiaolei, Zhu, Xiaodong, Ma, Yongzhou, Hu
openaire +2 more sources
Nature Reviews Molecular Cell Biology, 2021
DNA damage accumulation in zebrafish neurons during wakefulness is detected by Parp1, which induces a homeostatic drive to sleep and repair the damage.
openaire +2 more sources
DNA damage accumulation in zebrafish neurons during wakefulness is detected by Parp1, which induces a homeostatic drive to sleep and repair the damage.
openaire +2 more sources
The complex universe of inactive PARP1
Trends in GeneticsPoly(ADP-ribose) polymerase 1 (PARP1) is a crucial member of the PARP family, which modifies targets through ADP-ribosylation and plays key roles in a variety of biological processes. PARP inhibitors (PARPis) hinder ADP-ribosylation and lead to the retention of PARP1 at the DNA lesion (also known as trapping), which underlies their toxicity.
Doudou Huang +3 more
exaly +3 more sources
Novel PARP1 Inhibitors for Treating Cancer
ACS Medicinal Chemistry Letters, 2023Provided herein are novel PARP1 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
openaire +3 more sources
PARP1: A potential biomarker for gastric cancer
Pathology - Research and Practice, 2019Gastric cancer (GC) is the third leading cause of cancer mortality worldwide, with an overall 5-y survival rate of 25%. The majority of GCs are caused by infectious agents, including the bacterium Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV).
Hifza, Afzal +6 more
openaire +2 more sources
Olaparib, PARP1 inhibitor in ovarian cancer
Expert Opinion on Investigational Drugs, 2012Ovarian cancer is the most important cause of gynecological cancer-related mortality. Conventional treatments for advanced or recurrent disease offer limited results in terms of long-term responses and survival. Researches have recently focused on target therapies, which represent a new, promising, therapeutic approach, able to maximizing tumor kill ...
MARCHETTI, CLAUDIA +8 more
openaire +3 more sources